PDF herunterladen
Thromb Haemost 1998; 79(01): 169-176
DOI: 10.1055/s-0037-1614238
Review Article
Schattauer GmbH

Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form

Canio J. Refino
1   From the Departments of Cardiovascular Research, Cardiovascular Research
,
Nishit B. Modi
2   From the Departments oP Pharmacokinetics, South San Francisco CA, USA
,
Sherron Bullens
1   From the Departments of Cardiovascular Research, Cardiovascular Research
,
Cheryl Pater
1   From the Departments of Cardiovascular Research, Cardiovascular Research
,
Michael T. Lipari
1   From the Departments of Cardiovascular Research, Cardiovascular Research
,
Kirk Robarge
3   From the Departments of Bio Organic Chemistry, South San Francisco CA, USA
,
Brent Blackburn
3   From the Departments of Bio Organic Chemistry, South San Francisco CA, USA
,
Maureen Beresini
4   From the Departments of BioAnalytical Technology, Genentech Inc. South San Francisco CA, USA
,
Thomas Weller
5   From the Departments of Pharma Division, Preclinical Research, F. Hoffmann-La Roche LTD, Basel, Switzerland
,
Beat Steiner
5   From the Departments of Pharma Division, Preclinical Research, F. Hoffmann-La Roche LTD, Basel, Switzerland
,
Stuart Bunting
1   From the Departments of Cardiovascular Research, Cardiovascular Research
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 21. Januar 1997

Accepted after revision 14. August 1997

Publikationsdatum:
08. Dezember 2017 (online)

    Lizenzen und Reprints

Summary

Ro 44-3888 is a potent and selective antagonist of GP IIb/IIIa. Following IV administration to rhesus monkeys, the (mean ± SD.) clear ance, volume of distribution and terminal half-life of Ro 44-3888 were 4.4 ± 1.8 ml/min/kg, 0.8 ± 0.4 l/kg and 2.5 ± 0.8 h respectively. Oral administration of Ro 48-3657 (1 mg/kg), a doubly protected prodrug form, produced peak concentrations of Ro 44-3888 (152 ± 51 ng/ml), 4.2 ± 2.2 h after dosing. Terminal half-life and estimated bioavailabil ity were 5.1 ± 1.6 h and 33 ± 6% respectively. No effect on blood pressure, heart rate or platelet counts were seen. Adenosine diphosohate (ADP) induced platelet aggregation (PA) and cutaneous bleeding times (CBT) were determined prior to and after the last of 8 daily oral administrations of Ro 48-3657 (0.25 or 0.5 mg/kg) to eight rhesus monkeys. Peak and trough plasma concentrations were proportional to dose and steady state was achieved after the second administration. Inhibition of PA and prolongation of CBT were concentration dependent. The ex vivo IC50 (82 nM) for ADP-mediated PA correlated with a value (58 nM) determined in vitro. The CBT response curve was displaced to the right of the PA curve. CBT was prolonged to ≥25 min when levels of Ro 44-3888 exceeded 190 nM and PA was >90% inhibited. Therefore, in rhesus monkeys, Ro 48-3657 is reproducibly absorbed and converted to its active form, is well tolerated, and has a concentration-dependent effect on PA and CBT. These properties make Ro 48-3657 an attractive candidate for evaluation in patients at high risk for arterial thrombosis.

 

  • References

  • 1 Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989; 80: 1501-13.
    CrossrefPubMedGoogle Scholar
  • 2 Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17 suppl B 89B-95B.
    PubMedGoogle Scholar
  • 3 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
    CrossrefPubMedGoogle Scholar
  • 4 Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
    CrossrefPubMedGoogle Scholar
  • 5 Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-91.
    CrossrefPubMedGoogle Scholar
  • 6 Fuster V, Jang IK. Role of Platelet-inhibitor agents in coronary artery disease. In: Textbook of Interventional Cardiology. Topol EJ. (ed) Philadelphia, PA: W.B. Saunders; 1994: 3-22.
    Google Scholar
  • 7 Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld Jr. JW. Aspirin and Dipyridamole in the prevention of acute coronary thrombosis. Circulation 1987; 76: 125-34.
    CrossrefPubMedGoogle Scholar
  • 8 White HD, Charbonnier B, Van de Werf F, Erhardt L, David D, Hillis WS, von der Lippe G, Verheugt FWA, Jennings G, Braun D, Fitzpatrick V, Sax FL. An aspirin controlled study of MK-852 in patients with unstable angina (abstr). Circulation 1993; 88: I-201.
    PubMedGoogle Scholar
  • 9 Antiplatelet Trialists’ Collaboration.. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction and stroke by prolonged antiplatet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
    CrossrefPubMedGoogle Scholar
  • 10 O’Brien J. Effects of salicylates on human platelets. Lancet 1968; 1: 779-83.
    PubMedGoogle Scholar
  • 11 Saltiel E, Ward A. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet dependent disease states. Drugs 1987; 87: 222.
    PubMedGoogle Scholar
  • 12 Mills DCB, Puri R, Hu CJ, Minniti G, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analoques to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis Thromb 1992; 12: 430.
    CrossrefPubMedGoogle Scholar
  • 13 Grotemeyer K-H, Scharafinski H-W, Husstedt I-W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
    CrossrefPubMedGoogle Scholar
  • 14 Turitto VT, Baumgartner HR. Platelet surface interactions. In: Hemostasis and thrombosis, basic principles and clinical practices. Colman RW, Hirsh J, Marder VJ, Salzmann EW. ed. Philadelphia, PA: J. B. Lippencott Company; 1982: 364-79.
    Google Scholar
  • 15 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
    CrossrefPubMedGoogle Scholar
  • 16 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-43.
    PubMedGoogle Scholar
  • 17 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
    CrossrefPubMedGoogle Scholar
  • 18 Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.
    PubMedGoogle Scholar
  • 19 Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: Will they be useful when given chronically?. Circulation 1996; 94: 866-8.
    CrossrefPubMedGoogle Scholar
  • 20 The EPIC Investigators.. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
    CrossrefPubMedGoogle Scholar
  • 21 Topol EJ, Califf RM, Wiesman HF, Ellis SG, Tscheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
    CrossrefPubMedGoogle Scholar
  • 22 Blackburn BK, Gadek TR. GlycoproteinIIb/IIIa antagonists. Annu Rep Med Chem 1993; 28: 79-88.
    PubMedGoogle Scholar
  • 23 Weller T, Alig L, Hurzeler Muller M, Kouns WC, Steiner B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs of the future 1994; 19: 461-76.
    CrossrefPubMedGoogle Scholar
  • 24 Ojima L, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg med chem 1995; 3: 337-60.
    CrossrefPubMedGoogle Scholar
  • 25 Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ. for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995; 91: 2151-7.
    CrossrefPubMedGoogle Scholar
  • 26 Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver WD, McKee D, Fitzpatrick V, Sax FL. Randomized, double blind, placebo controlled dose ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536-42.
    CrossrefPubMedGoogle Scholar
  • 27 Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. on Behalf of the Investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study. Circulation 1996; 94 (06) 899-905.
    CrossrefPubMedGoogle Scholar
  • 28 Alig L, Edenhofer A, Hadvary P, Hurzeler M, Knopp D, Muller M, Steiner B, Trzeciak A, Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-407.
    CrossrefPubMedGoogle Scholar
  • 29 Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Muller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Muller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39 (16) 3139-47.
    CrossrefPubMedGoogle Scholar
  • 30 Tanswell P, Koup J. Topfit: a PC-based pharmacokinetics/pharmaco-dynamics data analysis program. Int J Clin Pharmacol Toxicol 1993; 31: 514-20.
    PubMedGoogle Scholar
  • 31 Beck WS. Hematology. (third ed.) Cambridge, Mass and London, England: MIT Press; 1983: 283.
    Google Scholar
  • 32 Folts JD, Smith SO. Acute platelet thrombus formation in stenosed monkey carotid arteries: inhibited with aspirin, restored temporarily with epinephrine (abstr). J AM Coll Cardiol 1985; 5: 468.
    PubMedGoogle Scholar
  • 33 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
    CrossrefPubMedGoogle Scholar
  • 34 Simoons ML, deBoer MJ, van den Brand MJ, van Miltenburg AJ, Hoomtje JCA, Heyndrickx GR. and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
    CrossrefPubMedGoogle Scholar
  • 35 Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harington RA, Lincoff Am, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Angerson HV, Nygaard TW, Mason SJ, Effron MB, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. The effects of Integrelin, a platelet glycoprotein IIb-IIIa receptor antagonist, in unstable angina: the importance of gender differences in the response to antiplatelet therapy. Circulation 1996; 94: 359-67.
    CrossrefPubMedGoogle Scholar
  • 36 Cannon CP, Novotny WF, McCabe CH, Tischler MD, Borzak S, Henry TD, Feldman R, Hamilton S, Rothman JM, Braunwald E. and the TIMI Investigators. Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48-3657 in patients post Acute Coronary Syndromes: primary results of the TIMI 12 Trial (abstr). Circulation 1996; 94 (08) I-552.
    PubMedGoogle Scholar
  • 37 Barrett JS, Murphy G, Peerlinck K, DeLepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Pharmacokinetics and pharmacodynamics of MK383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-88.
    CrossrefPubMedGoogle Scholar
  • 38 Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang C T-C, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, Lynch RJ, Manno PD, Schaffer LW, Smith RL. Non-peptide fibrinogen receptor antagonists. XX. Design and synthesis of the potent, orally active fibrinogen receptor antagonist L-734,217. J Med Chem 1995; 38: 3332-41.
    CrossrefPubMedGoogle Scholar
  • 39 Muller TH, Schurer H, Waldmann L, Bauer E, Himmelsbach F, Binder K. Oral activity of BIBU 104, a prodrug of the non-peptide fibrinogen receptor antagonist BIBU 52, in mice and monkeys (Abstr). Thromb Haemost 1993; 69: 675.
    PubMedGoogle Scholar
  • 40 Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Salzony JA, Haas MF, King LW, Zablocki JA, Keller BT, Broschat K. An orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-10.
    CrossrefPubMedGoogle Scholar
  • 41 Mousa SA, DeGrado WF, Mu D-X, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation 1996; 93: 537-43.
    CrossrefPubMedGoogle Scholar
  • 42 Funk C, Scheuermann G, Haas R, Viger-Chougnet A. Reduction of the aromatic amidoximes by subcellular fractions of rat liver. 2nd Annual Conference on Pharmacogenetics. Arlington, VA: 1996
    Google Scholar
  • 43 Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Skelly J, Batra V. ed. Toxicokinetics and new drug development. New York: Pergamon Press; 1989: 42-96.
    Google Scholar
  • 44 Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193-213.
    CrossrefPubMedGoogle Scholar
  • 45 Peerlink K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circulation 1993; 88: 1512-7.
    CrossrefPubMedGoogle Scholar
  • 46 Tschopp JF, Mazur C, Gould K, Connolly R, Pierschbacher MD. Inhibition of thrombosis by a selective fibrinogen receptor antagonist without effect on bleeding time. Thromb Haemost 1994; 72 (01) 119-24.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 47 Hawiger J, Kloczewiak M, Bednarek MA, Timmons S. Platelet receptor recognition domains on the A chain of human fibrinogen: structure-function analysis. Biochemistry 1989; 28: 2909-14.
    CrossrefPubMedGoogle Scholar
  • 48 Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471-5.
    PubMedGoogle Scholar
  • 49 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab’)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
    CrossrefPubMedGoogle Scholar
  • 50 Frank JD, Gould RJ, Schaffer LW, Davidson JT, Gibson RE, Patrick DH, Vonderfecht SL, Cartwright ME. Immunocytochemical localization of platelets in baboon hepatic sinusoids using monoclonal mouse anti-human platelet glycoprotein IIIa following induction of thrombocytopenia. Histochem 1992; 97: 355-60.
    CrossrefPubMedGoogle Scholar